{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:07:40Z","timestamp":1790330860995,"version":"4.1.0"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008648","name":"Pfizer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008648","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ctrv.2021.102178","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T20:36:46Z","timestamp":1615408606000},"page":"102178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"Jordi","family":"Remon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Pignataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7653-9748","authenticated-orcid":false,"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2021.102178_b0005","article-title":"ROS1 rearrangements define a unique molecular class of lung cancers","author":"Bergethon","year":"201230863","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0010","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2021.102178_b0015","first-page":"300","article-title":"Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis","volume":"4","author":"Zhu","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0020","doi-asserted-by":"crossref","unstructured":"Yang J, Pyo J-S, Kang G. Clinicopathological significance and diagnostic approach of ROS1 rearrangement in non-small cell lung cancer: a meta-analysis: ROS1 in non-small cell lung cancer. Int J Biol Markers 2018:1724600818772194. https:\/\/doi.org\/10.1177\/1724600818772194.","DOI":"10.1177\/1724600818772194"},{"key":"10.1016\/j.ctrv.2021.102178_b0025","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jtho.2018.05.026","article-title":"Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice","volume":"13","author":"Park","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0030","article-title":"Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer","author":"Digumarthy","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cllc.2019.06.012","article-title":"ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS)","volume":"21","author":"Chiari","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2020.01.017","article-title":"A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer","volume":"142","author":"Alexander","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0045","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jtho.2018.12.001","article-title":"ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events","volume":"14","author":"Ng","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0050","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jtho.2017.01.004","article-title":"ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0055","article-title":"CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome","author":"Ou","year":"2019130201","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0060","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.lungcan.2018.12.011","article-title":"Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib","volume":"129","author":"Liu","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2021.102178_b0070","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jtho.2019.07.005","article-title":"Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study","volume":"14","author":"Conde","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0075","doi-asserted-by":"crossref","first-page":"e421","DOI":"10.1016\/j.cllc.2019.02.008","article-title":"Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns","volume":"20","author":"Clav\u00e9","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0080","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1200\/JOP.19.00135","article-title":"Characteristics of Patients With ROS1+Cancers: Results From the First Patient-Designed, Global, Pan-Cancer ROS1Data Repository","volume":"16","author":"Parikh","year":"2020","journal-title":"JCO Oncology Practice"},{"key":"10.1016\/j.ctrv.2021.102178_b0085","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.jtho.2018.07.001","article-title":"The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib","volume":"13","author":"Patil","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0090","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.jtho.2018.04.016","article-title":"Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer","volume":"13","author":"Li","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0095","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/0008-5472.CAN-11-3990","article-title":"The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation","volume":"72","author":"Jun","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0100","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/0008-5472.CAN-18-1492","article-title":"Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins","volume":"79","author":"Neel","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0105","doi-asserted-by":"crossref","first-page":"9101","DOI":"10.1200\/JCO.2019.37.15_suppl.9101","article-title":"Crizotinib versus pemetrexed-based chemotherapy in patients with advanced ROS1-rearranged non-small cell lung cancer","volume":"37","author":"Shen","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2021.102178_b0110","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","author":"Shaw","year":"20143711963","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102178_b0115","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0120","article-title":"Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer","author":"Wu","year":"2018361405","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0125","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0130","article-title":"Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. JCO Precis","author":"Gainor","year":"20172017","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0135","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1158\/1078-0432.CCR-17-2452","article-title":"Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer","volume":"24","author":"McCoach","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0140","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1215530","article-title":"Acquired resistance to crizotinib from a mutation in CD74-ROS1","volume":"368","author":"Awad","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102178_b0145","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/1078-0432.CCR-16-0917","article-title":"Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers","volume":"22","author":"Facchinetti","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0150","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1158\/1078-0432.CCR-15-2013","article-title":"A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer","volume":"22","author":"Drilon","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0155","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-14-1350","article-title":"Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer","volume":"21","author":"Song","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0160","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2019.01.009","article-title":"Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC","volume":"14","author":"Dagogo-Jack","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0165","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial","volume":"20","author":"Shaw","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0170","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0175","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.jtho.2017.07.005","article-title":"ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC)","volume":"12","author":"Cho","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0180","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jtho.2019.03.002","article-title":"Efficacy and Safety of Ceritinib (450 mg\/d or 600 mg\/d) With Food Versus 750-mg\/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study","volume":"14","author":"Cho","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0185","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0190","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0195","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2021.102178_b0200","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.lungcan.2020.02.011","article-title":"Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer","volume":"144","author":"Peters","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0210","doi-asserted-by":"crossref","first-page":"v609","DOI":"10.1093\/annonc\/mdz260.011","article-title":"Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial","volume":"30","author":"Landi","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0215","doi-asserted-by":"crossref","unstructured":"Baldacci S, Avrillon V, Besse B et al. Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort. J Clin Oncol 38: 2020 (Suppl; Abstr 9615) n.d. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9615.","DOI":"10.1200\/JCO.2020.38.15_suppl.9615"},{"key":"10.1016\/j.ctrv.2021.102178_b0220","doi-asserted-by":"crossref","unstructured":"Zhu VW, Lin Y-T, Kim D-W, Loong HH, Nagasaka M, To H, et al. An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor\u2013Refractory ALK-Positive or ROS1-Positive NSCLC. Journal of Thoracic Oncology 2020:S1556086420303348. https:\/\/doi.org\/10.1016\/j.jtho.2020.04.019.","DOI":"10.1016\/j.jtho.2020.04.019"},{"key":"10.1016\/j.ctrv.2021.102178_b0225","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2020.07.022","article-title":"GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients","volume":"148","author":"Peled","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0230","article-title":"Repotrectinib (TPX-0005) Is a Next-Generation ROS1\/TRK\/ALK Inhibitor That Potently Inhibits ROS1\/TRK\/ALK Solvent- Front Mutations","author":"Drilon","year":"201881227","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2021.102178_b0235","article-title":"Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Na\u00efve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer","author":"Yun","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0240","doi-asserted-by":"crossref","first-page":"9011","DOI":"10.1200\/JCO.2019.37.15_suppl.9011","article-title":"Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study)","volume":"37","author":"Cho","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2021.102178_b0245","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1038\/s41467-019-11496-z","article-title":"The new-generation selective ROS1\/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models","volume":"10","author":"Katayama","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2021.102178_b0250","article-title":"First-in-human study of DS-6051b in patients (pts) with advanced solid tumors (AST) conducted in the US","author":"Papadopoulos","year":"2018362514","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2021.102178_b0255","doi-asserted-by":"crossref","first-page":"23729","DOI":"10.18632\/oncotarget.25263","article-title":"Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study","volume":"9","author":"Fujiwara","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2021.102178_b0260","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0265","doi-asserted-by":"crossref","unstructured":"Drilon A, Siena S, Ou S-HI, Patel M, Ahn MJ, Lee J, et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017;7:400\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1237.","DOI":"10.1158\/2159-8290.CD-16-1237"},{"key":"10.1016\/j.ctrv.2021.102178_b0270","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1016\/j.cllc.2020.03.008","article-title":"Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib","volume":"21","author":"De Giglio","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0275","doi-asserted-by":"crossref","unstructured":"Lin J, Johnson T, Lennerz J et al. Resistance to lorlatinib in ROS1 fusion-positive non-small cell lung cancer. J Clin Oncol 38: 2020 (Suppl; Abstr 9611) n.d. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.9611.","DOI":"10.1200\/JCO.2020.38.15_suppl.9611"},{"key":"10.1016\/j.ctrv.2021.102178_b0280","article-title":"Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer","author":"Ku","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2021.102178_b0285","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jtho.2019.03.020","article-title":"Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial","volume":"14","author":"Michels","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0290","doi-asserted-by":"crossref","first-page":"9066","DOI":"10.1200\/JCO.2019.37.15_suppl.9066","article-title":"Crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase II clinical trial\u2013Updated report on progression-free and overall survival","volume":"37","author":"Michels","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2021.102178_b0295","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3727\/096504019X15509372008132","article-title":"Different Types of ROS1 Fusion Partners Yield Comparable Efficacy to Crizotinib","volume":"27","author":"He","year":"2019","journal-title":"Oncol Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0300","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/1759-7714.12917","article-title":"PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1","volume":"10","author":"Lee","year":"2019","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0305","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0310","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000498","article-title":"Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion","volume":"4","author":"Berghoff","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2021.102178_b0315","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2021.102178_b0320","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-10-0851","article-title":"Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0325","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0330","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/cncr.26311","article-title":"Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement","volume":"118","author":"Kim","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0335","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/JTO.0000000000000030","article-title":"Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays","volume":"9","author":"Li","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0340","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","article-title":"Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists\/International Association for the","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0345","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"Lindeman","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0350","article-title":"Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS","author":"Niu","year":"20171871","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0355","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1158\/1538-7445.AM2018-4581","article-title":"Abstract 4581: Feasibility of an amplicon-based liquid biopsy for ALK and ROS1 fusions in advanced non-small cell lung cancer (NSCLC) patients. Clinical Research (Excluding Clinical Trials), American Association for","author":"Mezquita","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0360","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.jtho.2019.08.003","article-title":"Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer","volume":"14","author":"Horn","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0365","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.079","article-title":"Phase II\/III blood first assay screening trial (BFAST) in patients (pts) with treatment-na\u00efve NSCLC: Initial results from the ALK+ cohort","volume":"30","author":"Gadgeel","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0370","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1200\/JCO.2019.37.15_suppl.9019","article-title":"Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC)","volume":"37","author":"Shaw","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2021.102178_b0375","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0380","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1158\/1078-0432.CCR-19-1436","article-title":"Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity","volume":"25","author":"Dagogo-Jack","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0385","first-page":"1582","volume":"373","author":"First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102178_b0390","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0395","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0400","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2019.11.004","article-title":"Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial","volume":"15","author":"Huber","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0405","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(19)30252-8","article-title":"Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2021.102178_b0410","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102178_b0415","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","article-title":"Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study","volume":"29","author":"Gadgeel","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0420","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1200\/JCO.2020.38.15_suppl.9518","article-title":"Updated overall survival (OS) and safety data from the randomized, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALK + NSCLC","volume":"38","author":"Peters","year":"2020","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2021.102178_b0425","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2019.11.025","article-title":"Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"139","author":"Nakagawa","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0430","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ctrv.2021.102178_b0435","doi-asserted-by":"crossref","unstructured":"Camidge R, Kim HR, Ahn M-J, Yang JC-H, Han J-Y, Hochmair MJ, et al. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial. Annals of Oncology 2019;30:ix195\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdz446.","DOI":"10.1093\/annonc\/mdz446"},{"key":"10.1016\/j.ctrv.2021.102178_b0440","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial","author":"Camidge","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0445","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.jtho.2020.08.003","article-title":"ID:1882 Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3","volume":"15","author":"Selvaggi","year":"2020","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0450","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2021.102178_b0455","doi-asserted-by":"crossref","first-page":"v602","DOI":"10.1093\/annonc\/mdz260","article-title":"Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain","volume":"30","author":"Chow","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0460","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2021.102178_b0465","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/j.jtho.2018.06.005","article-title":"Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC","volume":"13","author":"Lin","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0470","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1111\/cas.13721","article-title":"Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9","volume":"109","author":"Hida","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2021.102178_b0475","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102178_b0480","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","article-title":"Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer","volume":"8","author":"Yoda","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2021.102178_b0485","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","article-title":"MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer","volume":"26","author":"Dagogo-Jack","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0490","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1508887","article-title":"Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F","volume":"374","author":"Shaw","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2021.102178_b0495","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1078-0432.CCR-19-1104","article-title":"Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2021.102178_b0500","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0505","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0510","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2020-0034","article-title":"Phase Ib Study of Crizotinib Plus Pembrolizumab in Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer with ALK Translocation","author":"Patel","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2021.102178_b0515","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jtho.2019.10.006","article-title":"Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study","volume":"15","author":"Felip","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0520","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0525","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2019.10.014","article-title":"Efficacy of Platinum\/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors","volume":"15","author":"Lin","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0530","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2019.08.010","article-title":"Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)","volume":"136","author":"Descourt","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2021.102178_b0535","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz260.067","article-title":"Brigatinib in ALK TKI-pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC): The use via expanded access to brigatinib (UVEA-Brig) study","volume":"30","author":"Novello","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2021.102178_b0540","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1200\/JCO.2019.37.15_suppl.9027","article-title":"Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC)","volume":"37","author":"Stinchcombe","year":"2019","journal-title":"JCO"},{"key":"10.1016\/j.ctrv.2021.102178_b0545","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1158\/1078-0432.CCR-17-2398","article-title":"Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I\/II","volume":"24","author":"Horn","year":"2018","journal-title":"Multicenter Study. Clin Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737221000268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:25:06Z","timestamp":1759656306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737221000268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":109,"alternative-id":["S0305737221000268"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102178","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2021.102178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102178"}}